IRAK

IRAK Related Products (25):

By Effects:	Inhibitors (19) Modulator (1) Degraders (5)

Cat. No.	Product Name	Effect	Purity

HY-13329

IRAK-1-4 Inhibitor I	Inhibitor	99.88%
IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC₅₀s of 0.2 μM and 0.3 μM, respectively.

HY-147264

Edecesertib	Inhibitor	99.86%
Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research.

HY-13276

IRAK inhibitor 2	Inhibitor	98.29%
IRAK inhibitor 2 is IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor .

HY-101922

IRAK4-IN-1	Inhibitor	99.88%
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-148290

KTX-951	Degrader	98.03%
KTX-951 is a PROTAC targeting IRAK4 degradation (DC₅₀=18 nM). KTX-951 (10 mg/kg) shows the oral bioavailability (F%) of 22% in a rat model. KTX-951 has good anticancer potential.

HY-W014223

2,4′-Dihydroxybenzophenone	Inhibitor
2,4′-Dihydroxybenzophenone (Ultraviolet absorber UV-0) occupies the hydrophobic pocket of MD2 and blocks the dimerization of TLR4. 2,4′-Dihydroxybenzophenone inhibits the LPS induced mtROS production, and LPS induced inflammatory response by downregulating pro-inflammatory mediators and decreasing the expression of MyD88, p-IRAK4, and NF-κB. 2,4′-Dihydroxybenzophenone is also a UV absorber.

HY-158434

IRAK1-IN-1	Inhibitor
IRAK1-IN-1 (compound B8) is an orally active IRAK1 inhibitor. IRAK1-IN-1 inhibits the release of IL-6 with the IC₅₀ values of 4.57 μM and 6.51 μM on mouse cells J774A. 1 and human cells THP-1, respectively. IRAK1-IN-1 alleviats LPS (HY-D1056)-induced acute lung injury (ALI) and DSS(HY-116282C)-induced colitis in mice.

HY-158758

PROTAC IRAK4 degrader-10	Degrader
PROTAC IRAK4 degrader-10 (compound 10) is an oral active PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 95.94% and the DC₅₀ of 7.68 nM in HEK293 cells (Sturcture Note:(Blue: Cereblon ligand, Black: linker；Pink: IRAK4 ligand).

HY-114181

IRAK4-IN-4	Inhibitor	99.85%
IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC₅₀ of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC₅₀ of 2.1 nM.

HY-13275

IRAK inhibitor 1	Inhibitor	99.83%
IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC₅₀ of 216 nM, is poorly active against JNK-1 and JNK-2 with IC₅₀ of 3.801 μM, and >10 μM, respectively.

HY-148274

KTX-582	Inhibitor	98.77%
KTX-582 is a potent IRAK4 degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model.

HY-151363

IRAK4-IN-21	Inhibitor	99.54%
IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.

HY-130253

IRAK4-IN-6	Inhibitor	99.92%
IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.

HY-13277

IRAK inhibitor 3	Modulator
IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.

HY-13278

IRAK inhibitor 4	Inhibitor	99.77%
IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

HY-13280

IRAK inhibitor 6	Inhibitor	99.75%
IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC₅₀ of 160 nM.

HY-151365

IRAK4-IN-22	Inhibitor	98.20%
IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.

HY-155132

IRAK4-IN-28	Inhibitor
IRAK4-IN-28 (compound 42) is an orally active IRAK4 inhibitor (IC₅₀=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases.

HY-153368

IRAK degrader-1	Degrader
IRAK degrader-1 (example I-3) is a potent IRAK degrader.

HY-120041

ND-2158	Inhibitor
ND-2158 is a competitive IRAK4 inhibitor, with the K_i of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo.

Name
Email *

	Sorry, but the email address you supplied was invalid.